Citations as recorded by:

1. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients

Br J Clin Pharmacol,

DOI: 10.1111/bcp.12747

Citations as recorded by: Cross Ref

2. Hypertension and Hepatitis C Virus Infection Are Strong Risk Factors for Developing Late Renal Dysfunction After Living Donor Liver Transplantation: Significance of Renal Biopsy

Transplantation Proceedings, 2014, 46(3) p. 804

DOI: 10.1016/j.transproceed.2013.11.103

Citations as recorded by: Cross Ref

3. Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients

Therapeutic Drug Monitoring, 2014, 36(4) p. 442

DOI: 10.1097/FTD.0000000000000032

Citations as recorded by: Cross Ref

4. CYP3A5genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients

Pediatr Transplantation, 2014, 18(2) p. 166

DOI: 10.1111/petr.12216

Citations as recorded by: Cross Ref

5. Immune Response following Liver Transplantation Compared to Kidney Transplantation: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity and Cytochrome P450 3A5 Genotype Assay

Clinical and Developmental Immunology, 2013, 2013 p. 1

DOI: 10.1155/2013/936063

Citations as recorded by: Cross Ref